161 related articles for article (PubMed ID: 24954745)
1. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck.
Yao M; Galanopoulos N; Lavertu P; Fu P; Gibson M; Argiris A; Rezaee R; Zender C; Wasman J; Machtay M; Savvides P
Head Neck; 2015 Nov; 37(11):1665-71. PubMed ID: 24954745
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Yao M; Woods C; Lavertu P; Fu P; Gibson M; Rezaee R; Zender C; Wasman J; Sharma N; Machtay M; Savvides P
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1770-6. PubMed ID: 26918562
[TBL] [Abstract][Full Text] [Related]
3. Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer.
Clark JI; Eisner RM; Hofmeister C; Norton J; Thomas S; Choudhury A; Petruzzelli G; Lathers D; Young MR; Lau A; Emami B
Am J Clin Oncol; 2009 Aug; 32(4):396-400. PubMed ID: 19415031
[TBL] [Abstract][Full Text] [Related]
4. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Kovács AF; Mose S; Böttcher HD; Bitter K
Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
6. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers.
Baykara M; Buyukberber S; Ozturk B; Coskun U; Unsal DK; Demirci U; Dane F; Kaplan MA; Bora H; Benekli M
Asian Pac J Cancer Prev; 2013; 14(4):2557-61. PubMed ID: 23725174
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.
Biete Solà A; Marruecos Querol J; Calvo Manuel FA; Verger Fransoy E; Rovirosa Casino A; Grau de Castro JJ; de Las Heras González M; Ramos Aguerri A; Palacios Eito A; Veiras Candal C; Solano López MV
Clin Transl Oncol; 2007 Apr; 9(4):244-50. PubMed ID: 17462977
[TBL] [Abstract][Full Text] [Related]
11. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
Specenier PM; Van den Weyngaert D; Van Laer C; Weyler J; Van den Brande J; Huizing MT; Dyck J; Schrijvers D; Vermorken JB
Ann Oncol; 2007 Nov; 18(11):1856-60. PubMed ID: 17823386
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Eswaran P; Azmi KS
J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
Adelstein DJ; Moon J; Hanna E; Giri PG; Mills GM; Wolf GT; Urba SG
Head Neck; 2010 Feb; 32(2):221-8. PubMed ID: 19557750
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers.
Baykara M; Buyukberber S; Ozturk B; Coskun U; Kaplan MA; Unsal DK; Dane F; Demirci U; Bora H; Benekli M;
Tumori; 2013; 99(4):469-73. PubMed ID: 24326834
[TBL] [Abstract][Full Text] [Related]
19. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
